Vinson & Elkins advised Lexicon Pharmaceuticals, while Simpson Thacher represented Invus on the deal. Cooley represented the underwriters for the public offering.Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
